113 related articles for article (PubMed ID: 2789150)
1. Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy.
Símová J; Bubeník J; Voitenok NN; Gren E
Folia Biol (Praha); 1989; 35(3):137-42. PubMed ID: 2789150
[TBL] [Abstract][Full Text] [Related]
2. Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice.
Bubeník J; Kieler J; Indrová M
Folia Biol (Praha); 1986; 32(3):209-11. PubMed ID: 3488924
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations.
Bubeník J; Indrová M; Toulcová A
Folia Biol (Praha); 1986; 32(6):384-91. PubMed ID: 3492396
[TBL] [Abstract][Full Text] [Related]
4. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumour efficacy of IL-1 and IL-2.
Bubeník J; Indrová M; Holán V
Folia Biol (Praha); 1988; 34(1):42-7. PubMed ID: 3260564
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
7. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of murine sarcomas with interleukin 2. II. Activation of killer cells by human recombinant IL-2.
Indrová M; Bubeník J; Toulcová A
Folia Biol (Praha); 1986; 32(6):392-8. PubMed ID: 3492397
[TBL] [Abstract][Full Text] [Related]
10. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
11. Chemoimmunotherapy of cancer: cyclophosphamide-resistant tumour cells are equally sensitive as the original tumour cell population to local IL-2 immunotherapy.
Símová J; Bubeník J; Jandlová T
Folia Biol (Praha); 1992; 38(2):122-8. PubMed ID: 1526289
[TBL] [Abstract][Full Text] [Related]
12. Intrasplenic administration of interleukin-2 to potentiate specific chemoimmunotherapy in tumor-bearing mice.
Nomi S; Naito K; Kahan BD; Pellis NR
Cancer Res; 1986 Nov; 46(11):5606-10. PubMed ID: 2875791
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.
Salup RR; Wiltrout RH
Cancer Res; 1986 Jul; 46(7):3358-63. PubMed ID: 3486710
[TBL] [Abstract][Full Text] [Related]
16. Active suppression of the proliferative response to interleukin-2 in tumour-bearing mice.
Zajícová A; Holán V
Folia Biol (Praha); 1990; 36(6):301-11. PubMed ID: 2279584
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy using local interleukin 2 administration.
Bubeník J; Indrová M
Immunol Lett; 1987 Dec; 16(3-4):305-9. PubMed ID: 3502122
[TBL] [Abstract][Full Text] [Related]
18. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
19. Changes in tumor-associated NK 1.1+ large granular lymphocyte precursors after cyclophosphamide injection: in vitro characterization and potential therapeutic application.
Krupke DM; Fuller J; Aslakson C; Evans R
Nat Immun; 1994; 13(5):246-57. PubMed ID: 7833624
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
Jürgenliemk-Schulz IM; Renes IB; Rutgers DH; Everse LA; Bernsen MR; Den Otter W; Battermann JJ
Radiat Oncol Investig; 1997; 5(2):54-61. PubMed ID: 9303058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
